For $5bn up front Gilead has effectively gained access to the Belgian company’s pipeline, in a deal that will tie the US biotech to Galapagos for many years to come.
Paying $40m up front for a preclinical asset is a bold move, even for the red-hot Nash space, though Boehringer has shelled out here before.
A China licensing deal from Genfit and the collapse of Conatus provide the latest news from the closely watched Nash space, which nervously awaits the next wave of…
On sales per employee Abbvie and Bristol-Myers Squibb lead the big pharma pack, while Sanofi and Astrazeneca are the sector laggards.
Pfizer’s Array buyout ranks as 2019’s second largest, but the price sits in a lonely space in the deal universe.
Beigene seeks very good data in Waldenström's macroglobulinaemia, while Galapagos aims to extend filgotinib's reach.
As placebo outperforms Cymabay’s seladelpar attention turns to the pivotal trial of Genfit’s elafibranor.
Amgen has gone further than anyone before to crack KRAS, but caution is required, as efficacy might ultimately not be as positive as initial data suggest.